BeOne Medicines (MEX:BGNEN) Construction In Progress: MXN2,520 Mil (As of Mar. 2026)


MEX:BGNEN BeOne Medicines Ltd MEX:BGNEN
81 GF Score
Price MXN2,858.16
GF Value MXN3,774.03
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Construction In Progress?

BeOne Medicines MEX:BGNEN 81 Construction In Progress is MXN2,520 Mil as of Mar. 2026. GuruFocus rates MEX:BGNEN with a GF Score™ of 81/100 and a GF Value™ of MXN3,774.03. The stock has 4 warning signs investors should review.

BeOne Medicines's quarterly construction in progress declined from Sep. 2025 (MXN2,415 Mil) to Dec. 2025 (MXN2,379 Mil) but then increased from Dec. 2025 (MXN2,379 Mil) to Mar. 2026 (MXN2,520 Mil).

BeOne Medicines's annual construction in progress increased from Dec. 2023 (MXN12,642 Mil) to Dec. 2024 (MXN13,764 Mil) but then declined from Dec. 2024 (MXN13,764 Mil) to Dec. 2025 (MXN2,379 Mil).

BeOne Medicines Construction In Progress Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Construction In Progress Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,122.97 6,153.95 12,641.72 13,763.62 2,378.97

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,140.26 6,750.44 2,415.45 2,378.97 2,519.80
MEX:BGNEN
81GF Score
BeOne Medicines Ltd MEX:BGNEN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN2,520 Mil mean?
BeOne Medicines (MEX:BGNEN) has a Construction In Progress of MXN2,520 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Construction In Progress too high?
BeOne Medicines' current Construction In Progress is MXN2,520 Mil. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Construction In Progress compare to RVMD and RPRX?
BeOne Medicines' Construction In Progress of MXN2,520 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Construction In Progress is MXN2,520 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Construction In Progress of MXN2,520 Mil. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Construction In Progress is MXN2,520 Mil. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Construction In Progress is MXN2,520 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.

Key valuation signals for MEX:BGNEN:

  • Construction In Progress: MXN2,520 Mil
  • GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for MEX:BGNEN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,858.16
Price
MXN3,774.03
GF Value